# the Effects and Safety of Idarubicin-strengthened Pretreatment Program and Conventional Busulfan Cyclophosphamide Pretreatment Program on High-risk Acute Myeloid Leukemia Patient

> **NCT01766375** · PHASE3 · UNKNOWN · sponsor: **Guangxi Medical University** · enrollment: 200 (estimated)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Cyclosporin A,mycophenolate mofetil,Methotrexate

## Key facts

- **NCT ID:** NCT01766375
- **Lead sponsor:** Guangxi Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-08
- **Primary completion:** 2016-01
- **Final completion:** 2016-06
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2013-01-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01766375

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01766375, "the Effects and Safety of Idarubicin-strengthened Pretreatment Program and Conventional Busulfan Cyclophosphamide Pretreatment Program on High-risk Acute Myeloid Leukemia Patient". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01766375. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*